Cancer Center Valle - San Pedro Garza Garcia, Mexico

Oncare

Ulcer

Colitis

Ulcerative Colitis

Guselkumab

Janssen (J&J Innovative Medicine)

condition

allSponsorName

gender

Male

Female

overallStatus

Recruiting

Not yet recruiting

Active, not recruiting

Enrolling by invitation

Completed

Terminated

Withdrawn

Suspended

Unknown

type

Interventional

Observational

Expanded Access

phase

Early Phase 1

Phase 1

Phase 2

Phase 3

Phase 4

Not Applicable

funderTypes

Industry

Other U.S. Federal agency

All others

ageGroup

Child (birth-17)

Adult (18-64)

Older Adult (65+)

The purpose of this study is to evaluate the efficacy, including clinical remission of guselkumab subcutaneous (SC) induction compared to placebo in participants with moderately to severely active ulcerative colitis (UC).

A Study of Guselkumab Therapy in Participants With Moderately to Severely Active Ulcerative Colitis

Oncare | Cancer Center Valle - San Pedro Garza Garcia, Mexico

Site insights

Work at this site?

Active trials

A Study of Guselkumab Therapy in Participants With Moderately to Severely Active Ulcerative Colitis (ASTRO)

Trial sponsors